论文部分内容阅读
目的探讨抗甲状腺药物(ATD)致粒细胞缺乏症的作用机制,提高诊治水平。方法对抗甲状腺药物致11例粒细胞缺乏症的临床资料进行分析。结果 ATD引起粒细胞缺乏症多发生于初始治疗的最初2～3个月或再次用药的1～2个月。采取停用ATD,使用粒细胞集落刺激因子(G-CSF)、广谱抗生素、消毒隔离等综合治疗,效果明显。结论接受ATD治疗患者,若治疗中出现发热、咽痛、全身不适等症状时立即查白细胞,以及时发现粒细胞缺乏的发生。
Objective To investigate the mechanism of anti-thyroid drug (ATD) agranulocytosis and to improve the diagnosis and treatment. Methods The clinical data of 11 cases of agranulocytosis induced by thyroid drugs were analyzed. Results ATD caused agranulocytosis mostly occurred in the initial treatment of 2 to 3 months or re-medication for 1 to 2 months. The withdrawal of ATD, the use of granulocyte colony stimulating factor (G-CSF), broad-spectrum antibiotics, disinfection and isolation and other comprehensive treatment, the effect is obvious. CONCLUSIONS: Patients receiving ATD should be treated immediately for signs of fever, sore throat, general malaise, and other signs of agranulocytosis, and for the timely detection of agranulocytosis.